株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

エンテカビルの中国市場の分析

Investigation Report on China Entecavir Market, 2010-2019

発行 China Research and Intelligence 商品コード 333477
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
エンテカビルの中国市場の分析 Investigation Report on China Entecavir Market, 2010-2019
出版日: 2015年06月18日 ページ情報: 英文 30 Pages
概要

中国国内のB型肝炎ウイルス (HBV) 感染者数は1億人以上に達し、そのうち2000〜3000万人が慢性B型肝炎を発症しています。慢性B型肝炎が原因の死亡者数は毎年50万人に達し、1000億人民元もの社会的損失が発生しています。デオキシグアノシン経口薬の一種であるエンテカビルは、抗ウイルス性が高く、効き目が速く、副作用が少ないといった特性があります。2005年5月にFDA (米国食品医薬品局) に認証され、2006年初頭から中国国内でも上市されるようになりました。2006年に3000万人民元だった売上高は、55%もの年平均成長率 (CAGR) で成長し、2014年には12億700万人民元に達しています。

当レポートでは、中国におけるエンテカビルの市場について分析し、全体的な市場規模や国内価格の動向、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通しなどを調査・推計しております。

第1章 エンテカビルの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のエンテカビル市場の概況

  • 中国国内でのエタネルセプト特許の出願・認証状況
  • 主要メーカー
  • 市場規模

第3章 エンテカビルの販売状況の分析 (過去5年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 中国のエンテカビル市場:主要メーカーの市場シェアの分析 (過去5年間分)

  • 市場シェア (販売額ベース)
  • 市場シェア (販売量ベース)

第5章 中国のエンテカビル市場:剤形別の分析 (過去5年間分)

  • 剤形別の市場シェア (販売額ベース)
  • 剤形別の市場シェア (販売量ベース)

第6章 エンテカビルの病院向け基準価格

第7章 中国国内のエンテカビルの主要メーカー

  • Sino-American Shanghai Squibb Pharmaceuticals Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • Jiangxi Qingfeng Pharmacy Co., Ltd
  • Fujian Cosunter Pharmaceutical Co., Ltd
  • Dawnrays Pharmaceutical Limited

第8章 中国のエンテカビル市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の見通し

図表一覧

目次
Product Code: 1506219

The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.

Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI's market survey, the annual sales value of entecavir in China rose from CNY 30 million in 2006 to CNY 1.207 billion in 2014 and CAGR during this period reached up to 55%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 60% in 2014 for sales value and over 50% for sales volume.

Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug's entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of entecavir in China
  • competitive landscape of entecavir in Chinese market
  • price of entecavir made by different manufacturers in China
  • market outlook of entecavir in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-HBV drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

Table of Contents

1. Related Concepts of Entecavir

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Entecavir in China

  • 2.1. Patent and Approval Status of Entecavir in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Entecavir in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Entecavir in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Entecavir in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Entecavir in China in 2014

  • 6.1. Sino-American Shanghai Squibb Pharmaceuticals Ltd (Trade Name: Baraclude)
  • 6.2. Sichuan Haisco Pharmaceutical Co., Ltd (Trade Name: Gan Bei Qing)
  • 6.3. Shandong Lukang Pharmaceutical Co., Ltd (Trade Name: Mu Chang)
  • 6.4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Run Zhong)
  • 6.5. Jiangxi Qingfeng Pharmacy Co., Ltd (Trade Name: Wei Li Qing)
  • 6.6. Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: En Gan Ding)
  • 6.7. Dawnrays Pharmaceutical Limited (Trade Name: Leiyide)

7Major Manufacturers of Entecavir in Chinese Market, 2010-2014

  • 7.1. Sino-American Shanghai Squibb Pharmaceuticals Ltd
  • 7.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.3. Jiangxi Qingfeng Pharmacy Co., Ltd
  • 7.4. Fujian Cosunter Pharmaceutical Co., Ltd
  • 7.5. Dawnrays Pharmaceutical Limited

8. Market Outlook of Entecavir in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Entecavir in China
  • Chart Approval Information of Entecavir in China
  • Chart Sales Status of Entecavir in China, 2010-2014
  • Chart Sales Value of Entecavir in China, 2010-2014
  • Chart Sales Value of Entecavir in Some Regions in China, 2010-2014
  • Chart Sales Volume of Entecavir in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Entecavir for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Shanghai Squibb in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Dawnrays in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Jiangxi Qingfeng in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Fujian Cosunter in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Other Manufacturers in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Capsules in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Tablets in China, 2010-2014
  • Chart Price of Entecavir Made by Sino-American Shanghai Squibb Pharmaceuticals Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Sichuan Haisco Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Shandong Lukang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Jiangxi Qingfeng Pharmacy Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Dawnrays Pharmaceutical Limited in Some Chinese Cities in 2014
Back to Top